AIV Logo AIV Assistant

Loading...

 Logo BioVie Inc. - BIVI 6.99 USD

EPS
-4.87
P/B
1.03
ROE
-208.26
Beta
0.90

6.990 USD

6.990 USD

Daily: +0.00%
Key Metrics

EPS: -4.87

Book Value: 2.51

Price to Book: 1.03

Debt/Equity: 39.41

% Insiders: 13.692%

Estimates

Forward P/E: -0.59

Forward EPS: -4.41

 Logo About BioVie Inc. - (BIVI)

Country: United States

Sector: Health Care

Website: http://www.biovieinc.com

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Exchange Ticker
NCM (Australia) BIVI

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Aug. 6, 2024 0.10
July 7, 2025 0.10
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion